✦ LIBER ✦

A Fresh Look at the Process of Arriving at a Clinical Prognosis Part 4: Fractures

✍ Scribed by James A. Orsini

Book ID: 113710031
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 171 KB
Volume: 32
Category: Article
ISSN: 0737-0806
DOI: 10.1016/j.jevs.2012.01.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Fresh Look at the Process of Arriving

A Fresh Look at the Process of Arriving at a Clinical Prognosis Part 2: Colic

✍ James A. Orsini 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 163 KB

A Fresh Look at the Process of Arriving

A Fresh Look at the Process of Arriving at a Clinical Prognosis Part 1: Laminitis

✍ James A. Orsini 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 150 KB

A Fresh Look at the Process of Arriving

A Fresh Look at the Process of Arriving at a Clinical Prognosis. Part 3: Neonatal Illness

✍ James A. Orsini 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 239 KB

IFCC primary reference procedures for th

IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37°C: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): Scientific Division, Committee on Reference Systems for Enzymes (C-RSE): Part 8. Reference procedure for the measurement of catalytic concentration of α-amylase: [α-Amylase: 1,4-α-D-glucan 4-glucanohydrolase (AMY), EC 3.2.1.1]

✍ Schumann, G.; Aoki, R.; Ferrero, C.A.; Ehlers, G.; Férard, G.; Gella, F.-J.; Jør 📂 Article 📅 2006 🏛 Walter de Gruyter GmbH & Co. KG 🌐 English ⚖ 117 KB

Can multiparametric magnetic resonance i

Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?11Mohamed Abd-Alazeez receives funding from the Egyptian government. Mark Emberton and Hashim U. Ahmed receive funding from USHIFU and Advanced Medical Diagnostics for clinical trials. Mark Emberton is a paid consultant for Steba Biotech, USHIFU and Sanofi-Aventis. Mark Emberton has received research support by GSK for a study evaluating the role of MRI in men with prostate cancer. Mark Emberton and Hashim Ahmed have previously received medical consultancy fees from GE Healthcare/Oncura and Hashim Ahmed previously from Steba Biotech. Mark Emberton is a medical director of Mediwatch PLC. Hashim Uddin Ahmed and Mark Emberton receive funding from the Medical Research Council, the NIHR-HTA, NIHR-i4i, the US NIH/NCI, Pelican Cancer Foundation, Prostate Cancer UK, and St Peter׳s Trust. This work was part funded by research support for Mark Emberton and Alex Kirkham from the UK National Institute of Health Research UCLH/UCL Comprehensive Biomedical Research Centre, London, UK.

✍ Abd-Alazeez, Mohamed; Ahmed, Hashim U.; Arya, Manit; Allen, Clare; Dikaios, Niko 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 415 KB